Related Experiment Video

Updated: Jul 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Management of hepatitis C virus infection in liver transplantation]

Marina Berenguer1

  • 1Servicio de Medicina Digestiva. Hospital Universitario La Fe. Valencia. España. mbhaym@teleline.es

Gastroenterologia Y Hepatologia
|August 30, 2006
PubMed

Insights

Liver transplant recipients with chronic hepatitis C virus (HCV) infection face poorer outcomes due to graft reinfection. Current antiviral therapies offer limited effectiveness and tolerability for preventing or treating HCV recurrence post-transplant.

Area of Science:

  • Hepatology
  • Virology
  • Transplantation Immunology

Context:

  • Liver transplantation is a life-saving procedure for end-stage liver disease.
  • Chronic hepatitis C virus (HCV) infection significantly complicates liver transplantation outcomes.
  • Graft reinfection and disease recurrence are major challenges in HCV-infected transplant recipients.

Purpose:

  • To evaluate the effectiveness and limitations of antiviral therapies in preventing and treating HCV recurrence after liver transplantation.
  • To compare early versus late treatment strategies for post-transplant HCV infection.
  • To identify the most effective and cost-efficient treatment options for managing HCV in liver transplant recipients.

Summary:

  • Patients transplanted for HCV-related cirrhosis have worse prognoses due to graft reinfection.
  • Pre-transplantation antiviral therapy has limited applicability and effectiveness.
  • Post-transplantation strategies include early treatment (limited applicability, 20-30% SVR) and treatment of established infection (35-45% efficacy with IFN/RBV).
  • Adverse effects like cytopenia and rejection limit treatment adherence, causing withdrawal in 30% of patients.

Impact:

  • Improved understanding of HCV recurrence challenges in liver transplantation.
  • Highlights the need for more effective and tolerable antiviral strategies.
  • Informs clinical decision-making regarding the timing and choice of antiviral therapy post-transplant.
  • Suggests that treatment of established HCV infection is currently the most cost-effective approach despite limitations.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...